# Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** medicenna.com
- **LinkedIn:** https://www.linkedin.com/company/medicenna-therapeutics-corp

## Regulatory record

- **Reports private funds:** No

## Questions

### What is Medicenna's primary therapeutic focus?

Medicenna focuses on engineered cytokines, specifically its Superkine platform, for cancer immunotherapy. Its lead asset, MDNA11, is a long-acting IL-2 Superkine targeting advanced solid tumors. The company also has pre-clinical programs including bispecific and CNS-penetrating Superkines.

### Does Medicenna participate in fund commitments or direct investments?

Medicenna does not make investments in other funds or companies. As a biotech firm, it raises capital through public offerings, private placements, and research grants to fund its internal R&D operations. It does not operate as an allocator of external capital.

### What is the source of Medicenna's funding?

Medicenna funds its operations through periodic public equity offerings, at-the-market (ATM) programs, and government grants. The company's most recent financing round was a $5 million private placement in December 2024 (per TSX filing).

### Which sectors does Medicenna explicitly avoid?

Medicenna focuses exclusively on oncology and immunotherapy applications of its Superkine platform. It does not diversify into other therapeutic areas, asset classes, or investment strategies. The firm avoids real estate, private equity, venture capital, or any non-biotech sectors.

## Related profiles

- [Graphex Group Ltd](https://altss.com/profile/graphex-group-ltd)
- [Vicapsys Life Sciences, Inc.](https://altss.com/profile/vicapsys-life-sciences-inc)

---

Last updated: 2026-07-11T10:07:30.000Z

Canonical page: https://altss.com/profile/medicenna-therapeutics-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology